Age-specific HPV seroprevalence among young females in the Netherlands

Sexually Transmitted Infections

Volumn 86, Issue 7, 2010, Pages 494-499

  Kramer, Merlijn ^a   Mollema, Liesbeth ^a   Smits, Gaby ^a   Boot, Hein ^a   De Melker, Hester ^a   Van Der Klis, Fiona ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; NETHERLANDS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SEROPREVALENCE; SEXUAL BEHAVIOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODIES, VIRAL; CHILD; COITUS; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 78649641634     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2009.041210     Document Type: Article

References (30)

1. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
2. Moscicki AB, Schiffman M, Kjaer S, et al. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 2006;24(Suppl 3):S42-51. (Pubitemid 44308674)
3. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. (Pubitemid 46986496)
4. Schiller JT, Castellsagué X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26 (Suppl 10):K53-61.
5. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009;374:301-14.
6. Wright TC Jr, Huh WK, Monk BJ, et al. Age considerations when vaccinating against HPV. Gynecol Oncol 2008;109:S40-7.
7. de Graaf H, Meijer S, Poelman J, et al. Seks onder je 25-: Seksuele gezondheid van jongeren in Nederland anno 2005. Utrecht: Rutgers Nissogroep/Soa Aids Nederland, 2005:7-55.
8. Smith JS, Melendy A, Rana RK, et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008;43:S5-S25.
9. Lenselink CH, Melchers WJG, Quint WGV, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in The Netherlands. PLoS ONE 2008;3:e3743.
10. Coupe VM, Berkhof J, Bulkmans NW, et al. Age-dependent prevalence of 14 highrisk HPV types in The Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008;98:646-51. (Pubitemid 351214513)
11. Ho GYF, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-16. (Pubitemid 38116628)
12. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-19.
13. Jit M, Vyse A, Borrow R, et al. Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer 2007;97:989-91. (Pubitemid 47519301)
14. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-19. (Pubitemid 46333946)
15. Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006;24(Suppl 3):S52-61. (Pubitemid 44293018)
16. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
17. Newall AT, Brotherton JM, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008;46:1647-55.
18. Markowitz LE, Sternberg M, Dunne EF, et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: national health and nutrition examination survey 2003-2004. J Infect Dis 2009:200:1059-67.
19. van der Klis FRM, Mollema L, Berbers GAM, et al. Second national serum bank for population-based seroprevalence studies in The Netherlands. Neth J Med 2009;67:301-8.
20. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005;12:959-69.
21. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003;10:108-15.
22. Cook JC, Joyce JG, George HA, et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein LI from Saccharomyces cerivisiae. Protein Expr Purif 1999;17:477-84.
23. Yeager MD, Aste-Amezaga M, Brown DR, et al. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 2000;278:570-7.
24. Anon. Statline Statistics Netherlands. http://statline.cbs.nl (accessed Jan 2009).
25. Dunne EF, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 in children. J Infect Dis 2005;191:1817-19.
26. Skjeldestad FE, Mehta V, Sings HL, et al. Seroprevalence and genital DNA prevalence of HPV types 6,11,16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008;87:81-8.
27. Barthell E, Woelber L, Hellner K, et al. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Arch Gynecol Obstet 2009;279:803-7.
28. Bakker F, de Graaf H, de Haas S, et al. Seksuele gezondheid in Nederland 2009. Utrecht: Rutgers Nisso Groep, 2009:5-90.
29. Koedijk FDH, Vriend HJ, van Veen MG, et al. Sexually transmitted infections, including HIV, in The Netherlands in 2008. Bilthoven: National Institute for Public Health and the Environment 2008:75-8.
30. Nielsen A, Krüger Kjaer S, Munk C, et al. Type-Specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008;35:276-82. (Pubitemid 351619532)